通过下一代测序和火烧测序来确定低风险骨髓质瘤瘤患者的突变概况,以了解疾病进展情况

Monika Adamska1,2, Ewelina Kowal-Wiśniewska1,3, Joanna Czerwińska-Rybak1

  • 1Department of Haematology and Bone Marrow Transplantation, Poznań University of Medical Sciences, Poznań, Poland.

Contemporary oncology (Poznan, Poland)
|February 26, 2024
PubMed
概括

下一代测序确定了较低风险的骨髓质瘤 (LR-MDS) 中的关键突变. 周围血液和唾液检测可以监测高风险的LR-MDS进展.